Related Experiment Video
Updated: Mar 13, 2026
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors
Gonzalo Lopez1, Raphael E Pollock2
1Division of Surgical Oncology, James Comprehensive Cancer Center, The Ohio State University, N-924 Doan Hall, 410W. 10th Avenue, Columbus, OH, 43210-1228, USA.
Abstract:
Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive disease with a dismal prognosis. The disease can occur sporadically or in patients with inherited neurofibromatosis (NF-1). MPNST is typically resistant to therapeutic intervention. Hence, the need for improved therapies is warranted. Several broad spectrum histone deacetylase (HDAC) inhibitors have a high affinity for class I HDAC isoforms. Inhibition of multiple HDAC isoforms often results in undesirable side effects, while inhibiting a single isoform could possibly improve the therapeutic window and limit toxicity. Recently, HDAC8 inhibitors have been developed and in initial preclinical studies, they demonstrate anticancer efficacy. Little is known about the role of HDAC8 in MPNST. We recently revealed an anticancer effect of HDAC8 inhibition in human and murine MPNST models. The goal of our previous study was to determine the potential therapeutic efficacy of HDAC8 inhibition in MPNST. In this chapter, we briefly describe the methods for determining the role of pharmacological HDAC inhibition in MPNST.
Insights
Targeting histone deacetylase 8 (HDAC8) shows promise for treating malignant peripheral nerve sheath tumors (MPNST). This approach may offer a more effective and less toxic therapy for this aggressive cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Malignant peripheral nerve sheath tumor (MPNST) is an aggressive cancer with poor outcomes.
- Current therapies for MPNST are largely ineffective, necessitating novel treatment strategies.
- Histone deacetylase (HDAC) inhibitors are being explored for cancer therapy, but broad-spectrum inhibitors cause significant side effects.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting histone deacetylase 8 (HDAC8) in MPNST.
- To evaluate the efficacy of targeting HDAC8 as a treatment strategy for MPNST.
- To explore the role of HDAC8 in the development and progression of MPNST.
Main Methods:
- Utilized human and murine MPNST models.
- Administered pharmacological HDAC8 inhibitors.
- Assessed the anticancer effects of HDAC8 inhibition.
Main Results:
- HDAC8 inhibition demonstrated anticancer efficacy in preclinical MPNST models.
- Targeting HDAC8 showed a potential therapeutic effect in MPNST.
- Further research is warranted to explore HDAC8 inhibition as a viable MPNST treatment.
Conclusions:
- Pharmacological inhibition of HDAC8 presents a promising therapeutic avenue for MPNST.
- Targeting specific HDAC isoforms, like HDAC8, may improve the therapeutic window and reduce toxicity compared to broad-spectrum inhibitors.
- These findings support the continued investigation of HDAC8 inhibitors for MPNST treatment.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:14Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
